3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Colorectal Neoplasms
8
Melanoma
6
Colonic Neoplasms
4
Rectal Neoplasms
3
Carcinoma, Non-Small-Cell Lung
3
Lung Neoplasms
2
Thyroid Neoplasms
1
Solid Tumors
1
Skin Neoplasms
1
Pancreatic Neoplasms
1
Neurofibromatosis 1
1
Neoplasms
1
Lymphatic Metastasis
1
Leukemia, Hairy Cell
1
Hereditary Sensory and Autonomic Neuropathies
1
Gastrointestinal Neoplasms
1
Disease Progression
1
Digestive System Neoplasms
1
Brain Neoplasms
1
Biliary Tract Neoplasms
1
Interventions
Specimen Handling
4
Fluorouracil
4
Bevacizumab
4
fludarabine
3
aldesleukin
3
Radiosurgery
3
Gemcitabine
3
Endoscopic Mucosal Resection
3
Cyclophosphamide
3
Cetuximab
3
130-nm albumin-bound paclitaxel
3
Surveys and Questionnaires
2
Sunitinib
2
Pemetrexed
2
Oxaliplatin
2
Leucovorin
2
IDRX-42
2
Folfox protocol
2
trastuzumab deruxtecan
1
tislelizumab
1
sodium thiosulfate
1
sodium propionate
1
semaglutide
1
repotrectinib
1
plecanatide
1
pembrolizumab
1
patritumab deruxtecan
1
palbociclib
1
linaclotide
1
isosorbide-5-mononitrate
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Gastrointestinal Neoplasms
×
encorafenib
×
90 days
×
Clear all
NCT05039177
2026-03-25
HERKULES-3
Erasca, Inc.
Phase 1/2
Completed
101 enrolled